<DOC>
	<DOCNO>NCT02668393</DOCNO>
	<brief_summary>Phase I study . To determine MTD ( Maximum Tolerated Dose ) nintedanib + weekly Docetaxel patient locally advance metastatic lung adenocarcinoma failure platinum-based first line chemotherapy .</brief_summary>
	<brief_title>Nintedanib Weekly Docetaxel Lung Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : Patients histologically/ cytologically confirm locally advanced ( Stage IIIB ) metastatic ( Stage IV ) lung adeno carcinoma failure first line platinum base chemotherapy ( patient nontarget lesion eligible ) . First line chemotherapy may include continuation switch maintenance therapy . One prior adjuvant and/or neoadjuvant chemotherapy line accept . Prior immunotherapy allow . ECOG inferior equal 1 screening . Further inclusion criterion apply Exclusion criterion : Patients receive one prior line chemotherapy ( i.e . second third line chemotherapy ) advance metastatic NSCLC . Patients know positive activate Epidermal Growth Factor Receptor ( EGFR ) mutation patient know positive ALK translocation Further exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>